January 30, 2019
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Read More
January 30, 2019
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Read More
X